|
Orthologous residues
|
|
CDK9 (human): T186‑p, CDK9 iso2 (human): T303‑p, CDK9 (mouse): T186‑p, CDK9 (rat): T186‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
mononuclear-blood
|
|
Cellular systems studied:
primary cells
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
|
|
CAMK1D (human)
|
|
increase
|
CaMK1-delta siRNA inhibits
|
|
LLnL
|
|
|
|
no change compared to control
|
|
|
phorbol ester, ionomycin
|
|
|
|
increase
|
|
|
thapsigargin
|
|
|
|
decrease
|
|
|
KN-93
|
|
|
|
decrease
|
|
|
KN-92
|
|
|
|
no change compared to control
|
|
|
W-7
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
protein stabilization
|
|
Comments:
decrease in phosphorylation precedes Cdk9 degradation
|